Immune surveillance and carcinogenesis - the role of endoplasmic reticulum stress in ovarian and renal cancers

VAVRUŠÁKOVÁ, Barbora, Lukáš MORÁŇ, Lenka KREJČÍ, Kamila SOUČKOVÁ, Kateřina VAŠÍČKOVÁ and Marek SVOBODA. Immune surveillance and carcinogenesis - the role of endoplasmic reticulum stress in ovarian and renal cancers. In XLVII. Brněnské onkologické dny, XXXVII. Konference pro nelékařské zdravotnické pracovníky Laboratorní diagnostika v onkologii. 2023.

Basic information

• Original name: Immune surveillance and carcinogenesis - the role of endoplasmic reticulum stress in ovarian and renal cancers
• Authors: VAVRUŠÁKOVÁ, Barbora (203 Czech Republic, belonging to the institution), Lukáš MORÁŇ (203 Czech Republic, belonging to the institution), Lenka KREJČÍ (203 Czech Republic, belonging to the institution), Kamila SOUČKOVÁ (203 Czech Republic, belonging to the institution), Kateřina VAŠÍČKOVÁ (203 Czech Republic, belonging to the institution) and Marek SVOBODA (203 Czech Republic, belonging to the institution).
• Edition: XLVII. Brněnské onkologické dny, XXXVII. Konference pro nelékařské zdravotnické pracovníky Laboratorní diagnostika v onkologii, 2023.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30204 Oncology
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/23:00134720
• Organization unit: Faculty of Medicine
• Keywords in English: carcinogenesis; immune surveillance; ovarian cancer; renal cancer

Abstract

Immune surveillance and carcinogenesis - the role of endoplasmic reticulum stress in ovarian and renal cancers - conference abstract.

Links

• NU21-03-00539, research and development project: Name: Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu

Investor: Ministry of Health of the CR, The effect of endoplasmic reticulum stress on the immune status of tumors and the efficiency of immunotherapy in the treatment of ovarian and renal cell carcinoma, Subprogram 1 - standard